FibroBiologics Repays Outstanding Debt, Focuses on Advancing Clinical Trials

FibroBiologics has paid off all outstanding convertible promissory notes to YA II PN, Ltd., eliminating its convertible debt. This financial milestone comes as the company advances towards key clinical and regulatory milestones, including the planned initiation of a Phase 1/2 clinical trial for its CYWC628 product candidate in early 2026. The company is also preparing to submit Investigational New Drug applications for CYPS317 and CYMS101.